Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.28 per share a year ago. These figures ...

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human ...

Reports Q4 revenue $1.58M, consensus $1.7M. “During 2024 and Q1 2025, we made significant progress shaping the company for success,” said ...